Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.

Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro.

Cancer immunotherapy, particularly T cell-based therapies, is considered to have strong potential for treating various types of cancer. A promising approach that has emerged is the use of γδ T cell-based strategies for cancer treatment. Neuroblastoma (NB), a solid tumor frequently found in childhood...

Full description

Saved in:
Bibliographic Details
Main Authors: Kuntida Kitidee, Sumet Amonyingcharoen, Sarinthip Preedagasamzin, Korakot Atjanasuppat, Piamsiri Sawaisorn, Pornprapa Srimorkun, Sawang Petvises, Wanpen Chaicumpa, Suparerk Borwornpinyo, Usanarat Anurathapan, Suradej Hongeng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0325389
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0325389

Similar Items